-
Don't Fall For The 'Defensive Portfolio' Hype
Monday, April 18, 2011 - 12:37pm | 263As the stock market has stalled and moved sideways since mid-February, with economic and inflationary worries increasing, Wall Street is beginning to put out advice on how to prepare for a potential market correction. The advice has always been the same. You've heard it before. No matter what...
-
Amarin Gains 75% On Drug Data (AMRN)
Monday, April 18, 2011 - 12:33pm | 139Amarin Corp. (NASDAQ: AMRN) is the largest percentage gainer on any stock exchange on Monday, rising around 75% to $15.30. The company announced positive clinical data from its ANCHOR trial on its drug candidate AMR101, which is used to treat high triglycerides in patients. The Phase III trial met...
-
Hearing Tier 1 Firm Upgrades Amarin; Raises PT To $21 (AMRN)
Monday, April 18, 2011 - 11:04am | 63Hearing Tier 1 Firm Upgrades Amarin; Raises PT To $21 (NASDAQ: AMRN). This article may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while unconfirmed information may be correlated with increased volatility in securities, price movements based on...
-
Puts Purchased on ViroPharma Incorporated (VPHM)
Monday, April 18, 2011 - 11:00am | 135Shares of ViroPharma Incorporated (NASDAQ: VPHM) are lower on the session by 9.67%, currently trading at $19.70. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name...
-
Top Narrow Based Indexes For April 18 (AMRN, TITN)
Monday, April 18, 2011 - 10:29am | 214By 10:25 am, the Dow Jones Industrial Average was down 207.75 points, or 1.68%, to 12,134.08, while the broader Standard & Poor's 500 index had dropped 20.56 points, or 1.56%. The NASDAQ composite index fell 49.97 points, or 1.81%. Some of the narrow based indexes that are supporting the...
-
Benzinga's Volume Movers (AMRN, TITN, THOR, HRBN)
Monday, April 18, 2011 - 10:17am | 159Amarin Corporation PLC (NASDAQ: AMRN) shares moved up 79.29% to $15.72 at 10:15 am. The volume of AMRN shares traded was 4056% higher than normal. AMRN reported significant top-line results from its ANCHOR trial for its lead product candidate, AMR101. Titan Machinery Inc (NASDAQ: TITN) shares rose...
-
NASDAQ Stocks Hitting 52-Week Highs (TITN, RGLD, AMRN, DOVR)
Monday, April 18, 2011 - 10:16am | 140Titan Machinery Inc (NASDAQ: TITN) shares rose 13.10% to create a new 52-week high of $30.47. TITN reported upbeat Q4 earnings. Royal Gold Inc (NASDAQ: RGLD) shares reached $56.07 to create a new 52-week high, before falling to $56.88, representing a 3.92% gain. RGLD is scheduled to report its Q3...
-
Jefferies Maintains Hold on Eli Lilly (LLY)
Monday, April 18, 2011 - 9:53am | 104Jefferies is out with its report today on Eli Lilly (NYSE: LLY), maintaining Hold. In a note to clients, Jefferies writes, "Q1 2011 results are better than consensus expectations due to a stronger top-line performance and better than expected operational margins. Non-GAAP 2011 EPS guidance has...
-
Morning Market Movers (AMRN, VLYWW, INVE, TITN)
Monday, April 18, 2011 - 9:51am | 103Amarin Corporation PLC (NASDAQ: AMRN) shares surged 79.06% to $15.70 at 9:45 am. AMRN reported significant top-line results from its ANCHOR trial for its lead product candidate, AMR101. Valley National Bancorp (NASDAQ: VLYWW) jumped 33.33% to $3.00. VLYWW's trailing-twelve-month operating margin...
-
Goldman Sachs Updates On PFE's Tofacitinib
Monday, April 18, 2011 - 8:57am | 116Goldman Sachs has issued a report regarding the P3 Oral Scan study of tofacitinib from Pfizer (NYSE: PFE). According to the report, “ORAL Scan (full data expected at ACR in Nov) adds new information on the JAK joint benefit (crucial for establishing a competitive profile with the biologicals, such...
-
Time To Look At J&J? Synthes Confirms Merger Talks (JNJ)
Monday, April 18, 2011 - 8:40am | 286Johnson & Johnson (NYSE: JNJ) is in talks to potentially acquire Synthes for approximately $20 billion, after the Swiss medical device maker confirmed the talks. If J&J were able to acquire Synthes for around $20 billion, it would be a fairly cheap deal, as it would only be approximately a...
-
J.P. Morgan Adjusting Estimates On Merck & Co
Monday, April 18, 2011 - 7:33am | 150According to J.P. Morgan, Merck & Co (NYSE: MRK) and JNJ announced a settlement on the Remicade / Simponi arbitration on Friday. J.P. Morgan reported that under the revised terms of the agreement, MRK will relinquish rights for roughly 30% of the current franchise and will accelerate the move...
-
A Peek Into The Market Before The Trading Starts
Monday, April 18, 2011 - 7:28am | 360Pre-open movers US stock futures are lower this morning. Futures on the Dow Jones Industrial Average dipped 72 points to 12,231.00 and futures on the S&P 500 stock index fell 9.20 points to 1,309.80. Nasdaq 100 futures dropped 14 points to 2,295.75. A Peek Into Global Markets Negative...
-
J.P. Morgan Asks: Do Johnson & Johnson's Synthes Pop
Monday, April 18, 2011 - 7:06am | 124According to J.P. Morgan, Johnson & Johnson (NYSE: JNJ) has for the last several months publicly discussed its interest in executing one or more large acquisitions. J.P. Morgan reported that this is why J&J is not buying back stock, despite pressure from shareholders and the fact that it's...
-
Eli Lilly Reports Upbeat Q1 Earnings
Monday, April 18, 2011 - 6:36am | 58Eli Lilly & Co (NYSE: LLY) reported its Q1 adjusted EPS at $1.24, beating the consensus of $1.16. LLY reported its Q1 revenue at $5.84 billion, versus the consensus of $5.70 billion. LLY shares gained 0.73% to close at $36.01 on Friday. Read more from Benzinga's Company news.